Enterprise Europe Network

A Dutch-British contract research organisation is looking for commercial agents for their preclinical in vitro immunology assay service

Country of origin:
Country: 
NETHERLANDS
Opportunity:
External Id: 
BONL20190806001
Published
03/09/2019
Last update
16/10/2019
Expiration date
16/10/2020

Keywords

Partner keyword: 
Clinical Research, Trials
Medical Research
In vitro Testing, Trials
Toxicology
Drug delivery and other equipment
Oncology
Medical Physics, Physiology
Pharmaceuticals/fine chemicals
Research and experimental development on biotechnology
Other human health activities
EXPRESS YOUR INTEREST

Summary

Summary: 
A Dutch-British company offers preclinical research for drug developing companies. The company provides various immunologic, in vitro, protein based and bioanalytical assays using cell lines and primary cells. In order to expand its commercial activities abroad, the company is looking for commercial agents to support their sales activities. A commercial agency agreement is envisioned.

Description

Description: 

A Dutch-British contract research organisation (CRO) is specialized in biological and analytical preclinical testing of novel drugs. The CRO is in particular highly specialised in immunology research and offers standard and customized biological and analytical assays for preclinical drug development. The company specialises in designing, developing and experimenting preclinical models to study immune response, immune risk and biological interactions.

Immune modelling is the modelling of a system to test the immune response that may be associated with a drug, an infection or a metabolite. To support drug developing companies, the CRO provides various immunologic, in vitro, protein based and bioanalytical assays using cell lines and primary cells. These are provided either as standard assays or as custom designed assays. Through their defined assays they help pharma companies and institutes to study drug impact on immune response, protein expression, cell to cell interaction, migration, proliferation, cell death and cytotoxicity, functional assays using gene knockdown, lymphocyte functions, cytokine expressions, etc.

The company is fast growing and recently opened a new laboratory facility in the UK. The CRO is now looking for commercial agents to support their sales activities. A commercial agency agreement is envisioned.

Advantages & innovations

Cooperation plus value: 
The use of cell lines in initial studies offers the advantage of minimal variability. In addition, it is a more cost-effective approach to gain insight in the immune response of drugs in the preclinical stage. The company is currently using an innovative and highly accurate platform of biological and analytical assays that combines novel cell lines, 3D scaffolds and primary cells to deliver an in vitro human cell-based immune system that mimics the in vivo human microenvironment.

Technical Specification or Expertise Sought

Cooperation sought: 
Expertise and experience is sought in the pharmaceutical field in particular in biological and analytical preclinical testing of novel drugs.

Stage of development

Cooperation stage dev stage: 
Already on the market

Partner sought

Cooperation area: 
The CRO is looking for companies, SMEs and or commercial agents, who are familiar with drug development, CRO activities and who have a commercial track record in the pharmaceutical field. The partner is expected to support the sales activities and set up other commercial activities with regard to the companies business proposition: preclinical research for drug developing companies.

Type and size

Cooperation task: 
SME 11-50,SME <10,251-500,SME 51-250,>500